Ari Nowacek is a co-founder and senior vice president of corporate development of City Therapeutics. Dr. Nowacek is applying his expertise in creating and scaling companies to realize City’s mission and pioneer the next generation of RNAi.

Dr. Nowacek has been a member of ARCH Venture Partners since 2016 and is a partner at the fund. While at ARCH, he has led company creation and placed investments across numerous fields including oncology, renal disease, autoimmune, immunology, gene therapy, coagulation and brain-computer interface.

Dr. Nowacek holds B.S. degrees in biology and psychology from the University of Indiana-Bloomington. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an MBA from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and postdoctoral research at the University of Chicago and Massachusetts General Hospital